Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

PAOLA-1 Study Surgical Subset for Ovarian Cancer

July 20th 2020

NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer

July 20th 2020

Personalized Dosing of Niraparib in Ovarian Cancer

July 20th 2020

Treating Homologous Recombination Proficient Ovarian Cancer

July 20th 2020

Treating BRCA+ Ovarian Cancer

July 20th 2020

Need for Frontline Comparison Trials in Ovarian Cancer

July 20th 2020

Impact of HRD Status on Frontline Treatment of Ovarian Cancer

July 20th 2020

The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer

July 20th 2020

Biomarker-Driven Frontline Ovarian Cancer Treatment

July 20th 2020

An Introduction to the Discussion of Ovarian Cancer

July 20th 2020

Dr. Moore on Unmet Clinical Needs in Platinum-Resistant Ovarian Cancer

July 17th 2020

Kathleen Moore, MD, discusses the unmet clinical needs in platinum-resistant ovarian cancer.

Dr. Gilbert on the Safety Profile of Mirvetuximab Soravtansine/Bevacizumab in Ovarian Cancer

July 16th 2020

Lucy Gilbert, MD, MSc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Public Mistrust May Undermine HPV and COVID-19 Vaccines

July 14th 2020

These are disquieting times for clear and decisive messaging regarding vaccines.

Olaparib Plus Bevacizumab Combination Expands Options in HRD+ Cancer

July 4th 2020

Shannon N. Westin, MD, MPH, discusses the rationale for administering the maintenance therapy in this setting and the broader potential of regimens combining PARP with other therapies.

Dr. Matulonis on the Current Treatment Landscape in Ovarian Cancer

July 2nd 2020

Ursula A. Matulonis, MD, discusses the current treatment landscape in ovarian cancer.

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

June 25th 2020

Dr. O’Malley on the Utility of Mirvetuximab in Ovarian Cancer

June 24th 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

Novel ADC STRO-002 Shows Early Promise in Heavily Pretreated Epithelial Ovarian Cancer

June 23rd 2020

R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.

Lipophilic Statin Use Is Associated With Decreased Mortality in Epithelial Ovarian Cancer

June 22nd 2020

Findings from an observational study of more than 10,000 women with ovarian cancer showed that lipophilic statins were associated with a 43% overall reduction in epithelial ovarian cancer mortality, with declines seen across subtypes.